# Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

> **NCT03182426** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alberta** · enrollment: 22 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Alemtuzumab
- **DRUG:** Anakinra
- **DRUG:** Etanercept
- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT03182426
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-15
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03182426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03182426, "Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03182426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*